Showing results (91-100 of 123) with videos related to
Sort By:
Pageof 13
Expert Review of Vaccines|September 5, 2024
A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and childrenFrances Priddy, Spyros Chalkias, Brandon Essink, et al.Open Forum Infectious Diseases|December 16, 2024
Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE TrialDean Follmann, Xiaowei Wang, Lindsey R Baden, et al.The Journal of Infectious Diseases|February 13, 2024
Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing VaccinesSpyros Chalkias, Nichole McGhee, Jordan L Whatley, et al.JAMA|May 7, 2025
Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years: A Randomized Clinical TrialAmanda K Rudman Spergel, Iris Wu, Weiping Deng, et al.The Journal of Infectious Diseases|November 25, 2025
A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure Proximal Design but Requires Far Fewer Blood SamplesDean Follmann, Lauren Dang, Eric Chu, et al.The Lancet. Infectious Diseases|March 22, 2024
Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trialAvika Dixit, Richard Bennett, Kashif Ali, et al.Gastroenterology|August 21, 2010
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rateMark S Sulkowski, Mitchell L Shiffman, Nezam H Afdhal, et al.Journal of Hepatology|April 22, 2014
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trialsJohn M Vierling, Stefan Zeuzem, Fred Poordad, et al.Nature Medicine|February 11, 2022
Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trialRolando Pajon, Yamuna D Paila, Bethany Girard, et al.The Lancet. Infectious Diseases|July 10, 2025
Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trialSpyros Chalkias, Patrick Dennis, Dena Petersen, et al.Pageof 13